The Role of Urinary Kidney Stone Inhibitors and Promoters in the Pathogenesis of Calcium Containing Renal Stones{A figure is presented}

EAU-EBU Update Series

Volumn 5, Issue 3, 2007, Pages 126-136

  Basavaraj, Doddametikurke Ramegowda ^a   Biyani, Chandra Shekhar ^a   Browning, Anthony J ^a   Cartledge, Jon J ^b  

^a PINDERFIELDS GENERAL HOSPITAL   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Crystal aggregation; Crystal growth; Nucleation; Urinary inhibitors

Indexed keywords

ACETAZOLAMIDE; CALCIUM; CALCIUM OXALATE; CALCIUM PHOSPHATE; CITRIC ACID; GLYCOSAMINOGLYCAN; HERMES ANTIGEN; HYALURONIC ACID; LITHOSTATHINE; MAGNESIUM; OSTEOPONTIN; OXALIC ACID; PHOSPHATE; PLACEBO; SODIUM; TAMM HORSFALL GLYCOPROTEIN; THIAZIDE DIURETIC AGENT; TREFOIL PEPTIDE; ULINASTATIN; URATE;

CALCIUM OXALATE STONE; CALCIUM STONE; CLINICAL TRIAL; CRYSTAL STRUCTURE; CRYSTALLIZATION; CRYSTALLURIA; DIET SUPPLEMENTATION; DRUG EFFICACY; DRUG MECHANISM; HUMAN; HYPOKALEMIA; KIDNEY CALCIFICATION; NEPHROLITHIASIS; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; REVIEW; SIDE EFFECT; STONE FORMATION; URINE PH; URINE VOLUME;

EID: 34247209738     PISSN: 18712592     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eeus.2007.03.002     Document Type: Review

References (82)

1. Pak C.Y. Kidney stones. Lancet 351 (1998) 1797-1801
2. Stamatelou K.K., Francis M.E., Jones C.A., et al. Time trends in reported prevalence of kidney stones in the United States: 1976-1994. Kidney Int 63 (2003) 1817-1823
3. Uribarri J., Oh M.S., and Carroll H.J. The first kidney stone. Ann Intern Med 111 (1989) 1006-1009
4. Randall A. An hypothesis for the origin of renal calculus. N Engl J Med (1936) 234-242
5. Finlayson B. Physicochemical aspects of urolithiasis. Kidney Int 13 (1978) 344-360
6. Kok D.J. Intratubular crystallization events. World J Urol 15 (1997) 219-228
7. Khan S.R., Byer K.J., Thamilselvan S., et al. Crystal-cell interaction and apoptosis in oxalate-associated injury of renal epithelial cells. J Am Soc Nephrol 10 Suppl 14 (1999) S457-S463
8. Lonsdale K. Epitaxy as a growth factor in urinary calculi and gallstones. Nature 217 (1968) 56-58
9. Finlayson B., and Reid F. The expectation of free and fixed particles in urinary stone disease. Invest Urol 15 (1978) 442-448
10. Boyce W.H., and Garvey F.K. The amount and nature of the organic matrix in urinary calculi: a review. J Urol 76 (1956) 213-227
11. Menon M, Resnick MI. Urinary lithiasis: etiology, diagnosis, and medical management. 8 ed. Campbell's Urology, ed. R. Walsh, Vaughn, Wein. Saunders, 2002. Chapter 96, p. 3229-92.
12. Evan A.P., Lingeman J.E., Coe F.L., et al. Randall's plaque of patients with nephrolithiasis begins in basement membranes of thin loops of Henle. J Clin Invest 111 (2003) 607-616
13. Matlaga B.R., Coe F.L., Evan A.P., and Lingeman J.E. The role of Randall's plaques in the pathogenesis of calcium stones. J Urol 177 (2007) 31-38
14. Bushinsky D.A. Nephrolithiasis: site of the initial solid phase. J Clin Invest 111 (2003) 602-605
15. Stoller M.L., Meng M.V., Abrahams H.M., and Kane J.P. The primary stone event: a new hypothesis involving a vascular etiology. J Urol 171 (2004) 1920-1924
16. Qiu S.R., Wierzbicki A., Orme C.A., et al. Molecular modulation of calcium oxalate crystallization by osteopontin and citrate. Proc Natl Acad Sci USA 101 (2004) 1811-1815
17. Hess B., Zipperle L., and Jaeger P. Citrate and calcium effects on Tamm-Horsfall glycoprotein as a modifier of calcium oxalate crystal aggregation. Am J Physiol 265 (1993) F784-F791
18. Blomen L.J. Growth and agglomeration of calcium oxalate monohydrate crystals. A contribution to the physico-chemistry of urinary stone formation (1982), Reichsuniversität Leiden
19. Hojgaard I., and Tiselius H.G. Crystallization in the nephron. Urol Res 27 (1999) 397-403
20. Verkoelen C.F., van der Boom B.G., Schroder F.H., and Romijn J.C. Cell cultures and nephrolithiasis. World J Urol 15 (1997) 229-235
21. Verkoelen C.F., Van Der Boom B.G., and Romijn J.C. Identification of hyaluronan as a crystal-binding molecule at the surface of migrating and proliferating MDCK cells. Kidney Int 58 (2000) 1045-1054
22. Schepers M.S., van der Boom B.G., Romijn J.C., et al. Urinary crystallization inhibitors do not prevent crystal binding. J Urol 167 (2002) 1844-1847
23. Verhulst A., Asselman M., Persy V.P., et al. Crystal retention capacity of cells in the human nephron: involvement of CD44 and its ligands hyaluronic acid and osteopontin in the transition of a crystal binding into a nonadherent epithelium. J Am Soc Nephrol 14 (2003) 107-115
24. Coe F.L., Nakagawa Y., Asplin J., and Parks J.H. Role of nephrocalcin in inhibition of calcium oxalate crystallization and nephrolithiasis. Miner Electrolyte Metab 20 (1994) 378-384
25. Wesson J.A., Johnson R.J., Mazzali M., et al. Osteopontin is a critical inhibitor of calcium oxalate crystal formation and retention in renal tubules. J Am Soc Nephrol 14 (2003) 139-147
26. Goldberg H., Grass L., Vogl R., et al. Urine citrate and renal stone disease. CMAJ 141 (1989) 217-221
27. Hamm L.L., and Hering-Smith K.S. Pathophysiology of hypocitraturic nephrolithiasis. Endocrinol Metab Clin North Am 31 (2002) 885-893 viii
28. Robertson W.G., Peacock M., and Nordin B.E. Inhibitors of the growth and aggregation of calcium oxalate crystals in vitro. Clin Chim Acta 43 (1973) 31-37
29. Francois B., Cahen R., and Pascal B. Inhibitors of urinary stone formation in 40 recurrent stone formers. Br J Urol 58 (1986) 479-483
30. Kok D.J., Papapoulos S.E., and Bijvoet O.L. Excessive crystal agglomeration with low citrate excretion in recurrent stone-formers. Lancet 1 (1986) 1056-1058
31. Hess B., Michel R., Takkinen R., Ackermann D., et al. Risk factors for low urinary citrate in calcium nephrolithiasis: low vegetable fibre intake and low urine volume to be added to the list. Nephrol Dial Transplant 9 (1994) 642-649
32. Pak C.Y. Citrate and renal calculi: new insights and future directions. Am J Kidney Dis 17 (1991) 420-425
33. He Y., Chen X., and Yu Z. The change of human Na+/dicarboxylate co-transporter 1 expression in the kidney and its relationship with pathogenesis of nephrolithiasis. Zhonghua Yi Xue Za Zhi 81 (2001) 1066-1069
34. Barcelo P., Wuhl O., Servitge E., et al. Randomized double-blind study of potassium citrate in idiopathic hypocitraturic calcium nephrolithiasis. J Urol 150 (1993) 1761-1764
35. Hofbauer J., Hobarth K., Szabo N., and Marberger M. Alkali citrate prophylaxis in idiopathic recurrent calcium oxalate urolithiasis-a prospective randomized study. Br J Urol 73 (1994) 362-365
36. Ettinger B., Pak C.Y., Citron J.T., et al. Potassium-magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis. J Urol 158 (1997) 2069-2073
37. Guerra A., Meschi T., Allegri F., et al. Concentrated urine and diluted urine: the effects of citrate and magnesium on the crystallization of calcium oxalate induced in vitro by an oxalate load. Urol Res 34 (2006) 359-364
38. Schwille P.O., Rumenapf G., Wolfel G., and Kohler R. Urinary pyrophosphate in patients with recurrent calcium urolithiasis and in healthy controls: a re-evaluation. J Urol 140 (1988) 239-245
39. Robertson W.G. Factors affecting the precipitation of calcium phosphate in vitro. Calcif Tissue Res 11 (1973) 311-322
40. Sharma S., Vaidyanathan S., Thind S.K., and Nath R. Urinary excretion of inorganic pyrophosphate by normal subjects and patients with renal calculi in north-western India and the effect of diclofenac sodium upon urinary excretion of pyrophosphate in stone formers. Urol Int 48 (1992) 404-408
41. Ettinger B. Recurrent nephrolithiasis: natural history and effect of phosphate therapy. A double-blind controlled study. Am J Med 61 (1976) 200-206
42. Rude R.K. Magnesium deficiency: a cause of heterogeneous disease in humans. J Bone Miner Res 13 (1998) 749-758
43. Desmars J.F., and Tawashi R. Dissolution and growth of calcium oxalate monohydrate. I. Effect of magnesium and pH. Biochim Biophys Acta 313 (1973) 256-267
44. Liebman M., and Costa G. Effects of calcium and magnesium on urinary oxalate excretion after oxalate loads. J Urol 163 (2000) 1565-1569
45. Reungjui S., Prasongwatana V., Premgamone A., et al. Magnesium status of patients with renal stones and its effect on urinary citrate excretion. BJU Int 90 (2002) 635-639
46. Salier J.P. Inter-alpha-trypsin inhibitor: emergence of a family within the Kunitz-type protease inhibitor superfamily. Trends Biochem Sci 15 (1990) 435-439
47. Tang Y., Grover P.K., Moritz R.L., et al. Is nephrocalcin related to the urinary derivative (bikunin) of inter-alpha-trypsin inhibitor?. Br J Urol 76 (1995) 425-430
48. Bauer J., and Reich Z. Uber die antitryptische. Wirkung des Harns. Med Klin 46 (1909) 1744-1747
49. Sorensen S., Hansen K., Bak S., and Justesen S.J. An unidentified macromolecular inhibitory constituent of calcium oxalate crystal growth in human urine. Urol Res 18 (1990) 373-379
50. Atmani F., Mizon J., and Khan S.R. Identification of uronic-acid-rich protein as urinary bikunin, the light chain of inter-alpha-inhibitor. Eur J Biochem 236 (1996) 984-990
51. Kobayashi H., Shinohara H., Gotoh J., et al. Anti-metastatic therapy by urinary trypsin inhibitor in combination with an anti-cancer agent. Br J Cancer 72 (1995) 1131-1137
52. Kobayashi H., Suzuki M., Hirashima Y., and Terao T. The protease inhibitor bikunin, a novel anti-metastatic agent. Biol Chem 384 (2003) 749-754
53. Okuyama M., Yamaguchi S., and Yachiku S. Identification of bikunin isolated from human urine inhibits calcium oxalate crystal growth and its localization in the kidneys. Int J Urol 10 (2003) 530-535
54. Atmani F., Opalko F.J., and Khan S.R. Association of urinary macromolecules with calcium oxalate crystals induced in vitro in normal human and rat urine. Urol Res 24 (1996) 45-50
55. O'Brien E.R., Garvin M.R., Stewart D.K., et al. Osteopontin is synthesized by macrophage, smooth muscle, and endothelial cells in primary and restenotic human coronary atherosclerotic plaques. Arterioscler Thromb 14 (1994) 1648-1656
56. Ophascharoensuk V., Giachelli C.M., Gordon K., et al. Obstructive uropathy in the mouse: role of osteopontin in interstitial fibrosis and apoptosis. Kidney Int 56 (1999) 571-580
57. Worcester E.M., and Beshensky A.M. Osteopontin inhibits nucleation of calcium oxalate crystals. Ann N Y Acad Sci 760 (1995) 375-377
58. Wesson J.A., Worcester E.M., Wiessner J.H., et al. Control of calcium oxalate crystal structure and cell adherence by urinary macromolecules. Kidney Int 53 (1998) 952-957
59. Nishio S., Hatanaka M., Takeda H., et al. Calcium phosphate crystal-associated proteins: alpha2-HS-glycoprotein, prothrombin F1, and osteopontin. Mol Urol 4 (2000) 383-390
60. Hedgepeth R.C., Yang L., Resnick M.I., and Marengo S.R. Expression of proteins that inhibit calcium oxalate crystallization in vitro in the urine of normal and stone-forming individuals. Am J Kidney Dis 37 (2001) 104-112
61. Yamate T., Tsuji H., Amasaki N., et al. Analysis of osteopontin DNA in patients with urolithiasis. Urol Res 28 (2000) 159-166
62. Grover P.K., and Ryall R.L. Inhibition of calcium oxalate crystal growth and aggregation by prothrombin and its fragments in vitro: relationship between protein structure and inhibitory activity. Eur J Biochem 263 (1999) 50-56
63. Webber D., Rodgers A.L., and Sturrock E.D. Synergism between urinary prothrombin fragment 1 and urine: a comparison of inhibitory activities in stone-prone and stone-free population groups. Clin Chem Lab Med 40 (2002) 930-936
64. Webber D., Radcliffe C.M., Royle L., et al. Sialylation of urinary prothrombin fragment 1 is implicated as a contributory factor in the risk of calcium oxalate kidney stone formation. Febs J 273 (2006) 3024-3037
65. Tamm I., and Horsfall Jr. F.L. Characterization and separation of an inhibitor of viral hemagglutination present in urine. Proc Soc Exp Biol Med 74 (1950) 106-108
66. Bachmann S., Dawnay A.B., Bouby N., and Bankir L. Tamm-Horsfall protein excretion during chronic alterations in urinary concentration and protein intake in the rat. Ren Physiol Biochem 14 (1991) 236-245
67. Serafini-Cessi F., Malagolini N., and Cavallone D. Tamm-Horsfall glycoprotein: biology and clinical relevance. Am J Kidney Dis 42 (2003) 658-676
68. Moe O.W. Kidney stones: pathophysiology and medical management. Lancet 367 (2006) 333-344
69. Mo L., Huang H.Y., Zhu X.H., et al. Tamm-Horsfall protein is a critical renal defence factor protecting against calcium oxalate crystal formation. Kidney Int 66 (2004) 1159-1166
70. Glauser A., Hochreiter W., Jaeger P., and Hess B. Determinants of urinary excretion of Tamm-Horsfall protein in non-selected kidney stone formers and healthy subjects. Nephrol Dial Transplant 15 (2000) 1580-1587
71. Knorle R., Schnierle P., Koch A., et al. Tamm-Horsfall glycoprotein: role in inhibition and promotion of renal calcium oxalate stone formation studied with Fourier-transform infrared spectroscopy. Clin Chem 40 (1994) 1739-1743
72. Rambausek M., Dulawa J., Jann K., and Ritz E. Tamm Horsfall glycoprotein in diabetes mellitus: abnormal chemical composition and colloid stability. Eur J Clin Invest 18 (1988) 237-242
73. Angell A.H., and Resnick M.I. Surface interaction between glycosaminoglycans and calcium oxalate. J Urol 141 (1989) 1255-1258
74. Roberts S.D., and Resnick M.I. Glycosaminoglycans content of stone matrix. J Urol 135 (1986) 1078-1083
75. Ryall R.L. Glycosaminoglycans, proteins, and stone formation: adult themes and child's play. Pediatr Nephrol 10 (1996) 656-666
76. 3 crystal growth. Eur J Clin Invest 22 (1992) 469-474
77. Geider S., Dussol B., Nitsche S., et al. Calcium carbonate crystals promote calcium oxalate crystallization by heterogeneous or epitaxial nucleation: possible involvement in the control of urinary lithogenesis. Calcif Tissue Int 59 (1996) 33-37
78. Grover P.K., Kim D.S., and Ryall R.L. The effect of seed crystals of hydroxyapatite and brushite on the crystallization of calcium oxalate in undiluted human urine in vitro: implications for urinary stone pathogenesis. Mol Med 8 (2002) 200-209
79. Ribieras S., Tomasetto C., and Rio M.C. The pS2/TFF1 trefoil factor, from basic research to clinical applications. Biochim Biophys Acta 1378 (1998) F61-F77
80. Chutipongtanate S., Nakagawa Y., Sritippayawan S., et al. Identification of human urinary trefoil factor 1 as a novel calcium oxalate crystal growth inhibitor. J Clin Invest 115 (2005) 3613-3622
81. Pillay S.N., Asplin J.R., and Coe F.L. Evidence that calgranulin is produced by kidney cells and is an inhibitor of calcium oxalate crystallization. Am J Physiol 275 2 Pt 2 (1998) F255-F261
82. Lieske J.C., Swift H., Martin T., et al. Renal epithelial cells rapidly bind and internalize calcium oxalate monohydrate crystals. Proc Natl Acad Sci USA 91 (1994) 6987-6991